ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
GlaxoSmithKline Pharmaceuticals Limited
GLAXOGlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India. Address: GSK House, Mumbai, India, 400030
Analytics
מחיר יעד של וול סטריט
246 072.23 INRיחס רווח למחיר
61.7219תשואת דיבידנד
1.8 %השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח GLAXO
ניתוח דיבידנדים GLAXO
גידול דיבידנד במשך 5 שנים
-39 %צמיחה מתמשכת
–יחס תשלום ממוצע של 5 שנים
187 %היסטוריית דיבידנדים GLAXO
שווי מניות GLAXO
פיננסיים GLAXO
תוצאות | 2019 | דינמיקה |